The pleural diseases market involves a variety of therapeutic interventions for treating pleural effusions and pneumothorax. Pleural drainage tubes are prominently used for draining fluid and air from the pleural space, providing relief to patients suffering from congestive heart failure or pneumonia. The global pleural diseases market is estimated to be valued at US$ 42,388.8 Mn in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growth Accelerated by Increasing Prevalence of Lung Cancer and Tuberculosis
The prevalence of lung cancer and tuberculosis has accelerated remarkably in recent years. According to the World Health Organization (WHO), lung cancer accounted for over 2.1 million new cases in 2018, making it the most common cancer worldwide. Additionally, around 10 million new tuberculosis cases are reported annually. The increasing incidence of these diseases has significantly driven the need for therapeutic interventions in the pleural diseases market. Novel product approvals and upgrading of existing therapies by major players will further aid the market growth over the forecast period.
Segment Analysis
The global pleural diseases market is segmented based on type, treatment, end user and geography. By type, the market is segmented into malignant and non-malignant pleural diseases. Malignant pleural diseases dominates the market and accounts for over 60% share owing to increasing cases of lung cancer and mesothelioma. Treatment-wise, the market is categorized into drugs, surgery and brachytherapy. Drugs hold the largest share as they are the first line of treatment for pleural diseases and have minimum side effects and risks compared to surgery and brachytherapy. The end user segment includes hospitals, clinics, cancer treatment centers and others. Hospitals hold the major share since majority of the surgeries and brachytherapy procedures are carried out in hospitals.
Key Takeaways
The global pleural diseases market is expected to witness high growth over the forecast period driven by increasing prevalence of lung cancer and mesothelioma.
Regional Analysis: North America dominates the global market owing to increasing incidence of malignant pleural diseases and presence of advanced healthcare facilities. According to American Cancer Society, lung cancer accounts for 25% of all cancer deaths in the United States each year.
Key players operating in the pleural diseases market are Abbvie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, and Merck & Co. Inc. AbbVie dominates the market with its blockbuster drug Humira which is approved for treatment of various types of cancer including malignant pleural mesothelioma. Amneal Pharmaceuticals launched a generic version of carboplatin injection in 2019, expanding its portfolio in the oncology segment.
